Top Markets
Coin of the day
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
Classifica tra le azioni #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-04-02
Capitalizzazione di mercato
$14.51K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
9,900.00%
Paese
US
Scambia Q BioMed Inc. (QBIO)

Categoria

Storico del rendimento da dividendi per Q BioMed Inc. (QBIO)
Il rendimento da dividendi (TTM) di Q BioMed Inc. (simbolo azionario: QBIO) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Q BioMed Inc. (QBIO) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.65%
BE
0.00%
KR